Literature DB >> 14028943

Failure of relaxin inthe treatment of scleroderma.

J E JEFFERIS, A S DIXON.   

Abstract

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID; RELAXIN; SCLERODERMA

Mesh：

Substances：

Year:  1962        PMID： 14028943      PMCID： PMC1007291          DOI： 10.1136/ard.21.3.295

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Digital arteries in rheumatoid disease.

Authors:  J T SCOTT; D O HOURIHANE; F H DOYLE; R E STEINER; J W LAWS; A S DIXON; E G BYWATERS
Journal:  Ann Rheum Dis       Date:  1961-09       Impact factor: 19.103

2.  Relaxin: its effects in a case of acrosclerosis.

Authors:  G ISMAY
Journal:  Br J Dermatol       Date:  1958-05       Impact factor: 9.302

3.  Use of relaxin in the treatment of scleroderma.

Authors:  G G CASTEN; R J BOUCEK
Journal:  J Am Med Assoc       Date:  1958-01-25

4.  Effects of administration of relaxin to human subjects.

Authors:  G T PERKOFF; H A SALHANICK; M X ZARROW; D H NELSON; F H TYLER
Journal:  J Clin Endocrinol Metab       Date:  1954-05       Impact factor: 5.958
  4 in total
  3 in total

1.  Failure of low molecular weight dextran infusions in scleroderma.

Authors:  J A Kirk; A S Dixon
Journal:  Ann Rheum Dis       Date:  1969-01       Impact factor: 19.103

Review 2.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 3.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.